Want to see CLYM full AI Analyst Report?
Top Page
Climb Bio
(NASDAQ:CLYM)
Select Model
Select Model
Rating:58Neutral
Price Target:
$16.00
▼(-0.50% Downside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by pre-revenue financials with ongoing losses and cash burn, partially offset by a strong, low-debt balance sheet. Technicals are moderately supportive, and corporate events are positive on clinical progress but tempered by dilution risk from the new ATM program. Valuation provides limited support given the negative P/E and no dividend yield.
Positive Factors
Differentiated CLYM116 clinical profile
CLYM116’s extended half-life, sustained biomarker suppression, and favorable early tolerability support a potentially differentiated treatment profile in IgA nephropathy. The planned every-12-week regimen and patient-friendly delivery work could improve convenience and strengthen future commercial positioning.
Negative Factors
No commercial revenue
With no reported revenue, Climb Bio has not yet demonstrated commercial traction or an operating model supported by product sales. Its future financial performance therefore depends heavily on clinical execution, regulatory progress, and eventual successful commercialization of pipeline therapies.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated CLYM116 clinical profile
CLYM116’s extended half-life, sustained biomarker suppression, and favorable early tolerability support a potentially differentiated treatment profile in IgA nephropathy. The planned every-12-week regimen and patient-friendly delivery work could improve convenience and strengthen future commercial positioning.
Read all positive factors
Climb Bio (CLYM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$864.42M
Dividend YieldN/A
Average Volume (3M)1.41M
Price to Earnings (P/E)―
Beta (1Y)1.73
Revenue GrowthN/A
EPS Growth-19.29%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.83
Shares Outstanding57,436,256
10 Day Avg. Volume1,759,805
30 Day Avg. Volume1,406,553
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.97
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.11Price Target Upside74.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.79
Revenue Forecast (FY)N/A
Climb Bio Business Overview & Revenue Model
Company Description
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is ...
Climb Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -68.00K | -97.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -59.35M | -59.75M | -30.36M | -35.12M | -45.24M | -47.48M |
| Net Income | -57.62M | -59.85M | -73.90M | -35.12M | -45.24M | -47.48M |
Balance Sheet | ||||||
| Total Assets | 246.29M | 167.74M | 217.19M | 110.47M | 134.99M | 173.24M |
| Cash, Cash Equivalents and Short-Term Investments | 183.12M | 101.08M | 150.92M | 106.80M | 123.57M | 136.48M |
| Total Debt | 1.31M | 541.00K | 532.00K | 349.00K | 480.00K | 0.00 |
| Total Liabilities | 6.75M | 7.27M | 5.31M | 2.87M | 6.28M | 6.04M |
| Stockholders Equity | 239.55M | 160.47M | 211.88M | 107.60M | 128.72M | 167.20M |
Cash Flow | ||||||
| Free Cash Flow | -53.07M | -54.54M | -15.56M | -20.60M | -37.37M | -36.07M |
| Operating Cash Flow | -52.70M | -54.36M | -15.56M | -20.60M | -37.37M | -36.07M |
| Investing Cash Flow | -29.42M | 2.83M | -121.09M | 68.98M | 34.44M | -114.97M |
| Financing Cash Flow | 103.69M | -21.00K | 130.73M | 841.00K | 0.00 | 177.23M |
Climb Bio Technical Analysis
Neutral
16.08
Price Trends
14.17
Positive
12.54
Positive
8.91
Positive
Market Momentum
0.25
Positive
49.83
Neutral
60.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLYM, the sentiment is Neutral. The current price of 16.08 is above the 20-day moving average (MA) of 15.85, above the 50-day MA of 14.17, and above the 200-day MA of 8.91, indicating a neutral trend. The MACD of 0.25 indicates Positive momentum. The RSI at 49.83 is Neutral, neither overbought nor oversold. The STOCH value of 60.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CLYM.
Climb Bio Risk Analysis
Climb Bio disclosed 72 risk factors in its most recent earnings report. Climb Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Climb Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $864.42M | -18.01 | -31.79% | ― | ― | -19.29% | |
56 Neutral | $308.84M | 2.54 | -38.12% | ― | 30.47% | ― | |
53 Neutral | $527.30M | -5.48 | -23.64% | ― | -76.20% | 52.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $47.79M | -1.25 | 248.50% | ― | ― | 36.06% | |
48 Neutral | $94.14M | -5.10 | -50.17% | ― | ― | 70.27% | |
44 Neutral | $128.09M | -3.76 | -154.32% | ― | ― | 84.80% |
* Healthcare Sector Average
CLYM
Climb Bio
14.25
12.00
533.33%
AGEN
Agenus
6.94
2.46
54.91%
HURA
TuHURA Biosciences
2.05
-0.45
-18.00%
OVID
Ovid Therapeutics
2.69
1.43
113.49%
CGTX
Cognition Therapeutics
0.98
-1.19
-54.75%
TVGN
Tevogen Bio Holdings
7.36
-35.93
-83.00%
Climb Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
Climb Bio Reports Encouraging Initial Phase 1 CLYM116 Data
Positive
Sep 3, 2026
On September 3, 2026, Climb Bio reported positive initial Phase 1 data for CLYM116, its anti-APRIL monoclonal antibody, showing a roughly 29-day half-life, near-complete APRIL suppression, and 60-75% reductions in IgA and Gd-IgA1 levels for 12 wee...
Business Operations and StrategyProduct-Related Announcements
Climb Bio Advances Phase 2 Renal Disease Trial
Positive
Aug 14, 2026
On August 13, 2026, Beijing Mabworks Biotech Co., Ltd. and Climb Bio, Inc. reported that the first patient with immunoglobulin A nephropathy was dosed in a Phase 2 clinical trial in China. This milestone marks a key advancement in their joint drug...
Executive/Board Changes
Climb Bio Appoints Breanna O’Reilly to Board
Neutral
Jul 1, 2026
On June 29, 2026, Climb Bio, Inc. announced that Andrew Levin resigned from its board of directors with immediate effect, marking a change in the company’s governance lineup. On the same date, the board elected Breanna O’Reilly, Ph.D.,...
Business Operations and StrategyPrivate Placements and Financing
Climb Bio Establishes New At-the-Market Equity Program
Positive
Jun 12, 2026
On June 12, 2026, Climb Bio, Inc. entered into a new Open Market Sale Agreement with Jefferies LLC allowing the company to sell up to $100 million of its common stock from time to time in an at‑the‑market offering under an effective sh...
Business Operations and StrategyProduct-Related Announcements
Climb Bio Reports Encouraging Early Budoprutug ITP Data
Positive
Jun 11, 2026
On June 11, 2026, Climb Bio, Inc. reported initial data from the ongoing Phase 1b portion of its Phase 1b/2a trial of budoprutug in adults with primary immune thrombocytopenia, covering 15 heavily pretreated patients in 250 mg and 500 mg intraveno...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Climb Bio Shareholders Approve Equity Plan Amendment, Reelect Directors
Positive
Jun 8, 2026
At Climb Bio’s 2026 Annual Meeting of Stockholders held on June 5, 2026, shareholders approved an amendment to the 2021 Equity Incentive Plan to include prefunded warrants when calculating the automatic annual increase to the plan’s sh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.